| Autor: |
Ketteler, T., Krahwinkel, W., Wolfertz, J., Gödke, J., Hoffmeister, T., Scheuble, L., Gülker, H. |
| Zdroj: |
European Heart Journal; 1997, Vol. 18 Issue suppl_D, p24-30, 7p |
| Abstrakt: |
Arbutamine, a new potent non-selective β-adrenoceptor agonist with mild α1-sympathomimetic activity, has been developed specifically for pharmacological stress testing. The drug acts like physical exercise, increasing both heart rate and myocardial contractility. Sensitivity, specificity and accuracy in detecting significant stenotic coronary artery disease are 76%, 96%, and 82%, respectively, agian similar to those of exercise echocardiography.The drug is delivered by a computerized drug delivery and monitoring device (GenESA) which adjusts the infusion rate according to the patient's heart rate data feedback. The drug is generally well tolerated and has an acceptable safety profile.This article describes recent clinical experience with arbutamine and presents preliminary results of a multicentre multinational study which evaluates the clinical utility and safety of the GenESA system in diagnosing coronary artery disease. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
